NCT04434586View on ClinicalTrials.gov

Contribution of Optical Coherence Tomography in the Endovascular Treatment of Femoral Occlusions

NAUnknownINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

June 16, 2020

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions
Superficial Femoral Artery StenosisClaudicationIschemic Leg
Interventions
DEVICE

femoropopliteal revascularization for TASC C or TASC D lesion

Femoropopliteal revascularization: ATL or ATL/stenting for TASC C/D lesions. Control group: only angiography 2D final control. Experimental group: angiography + OCT control

Trial Locations (1)

59037

RECRUITING

Insitut Coeur-Poumon, CHU, Lille

Sponsors

Collaborators (1)

Abbott
All Listed Sponsors
collaborator

Abbott

INDUSTRY

lead

University Hospital, Lille

OTHER

NCT04434586 - Contribution of Optical Coherence Tomography in the Endovascular Treatment of Femoral Occlusions | Biotech Hunter | Biotech Hunter